Introduction
Oestrogens are able to regulate gene expression by binding to specific receptors that function as transcription factors [ 1-31. Hormone binding is required initially for the dissociation of an inactive, oligomeric, receptor complex to allow receptor dimerization and high-affinity DNA binding [4, 51 and, secondly, to produce the full transcriptional activity of the receptor [6-91. In view of the role of oestrogens as mitogens in certain types of cells and the observation that approximately 30% of breast cancer can be treated with endocrine therapy, a large number of anti-oestrogens have been developed as potential drugs. T o date these antioestrogens appear to fall into two groups. One group, which includes the non-steroidal antioestrogen tamoxifen, also act as partial agonists while another group, which includes ICI 164384, appear to act predominantly as 'pure' anti-oestrogens [ 10, 1 11. The molecular basis for the action of different ligands is now beginning to emerge and is the subject of this review.
Structure of the oestrogen receptor
The oestrogen receptor, in all species, has a molecular mass of approximately 66000, with 595 amino acids in the human protein. The receptor is organized into three distinct structural domains on the basis of protease-digestion experiments and studies of chimeric proteins (Fig. 1) 
Role of oestrogen in receptor activation
The oestrogen receptor, as with other steroid receptors, is activated as a transcription factor by hormone binding. In the absence of steroid the oestrogen receptor exists as an inactive oligomeric complex containing the heat-shock protein hsp 90, which appears to inhibit DNA binding [4] . Oestrogen binding results in dissociation of the complex thereby allowing receptor dimerization and high-affinity DNA binding [ 51. A region of the mouse oestrogen receptor has been identified which is essential for oestrogen binding and overlaps, but is not coincident with, a region involved in dimerization [ 121. The importance of this region for hormone binding is supported by the observation that cysteine 530 in the human oestrogen receptor is covalently labelled by both the oestrogen, ketononestrol aziridine, and the anti-oestrogen, tamoxifen aziridine, indicating that this residue is in close proximity to the ligand-binding pocket [ 141. The structure of the region is not known, but the mutagenesis data suggest that it does not resemble a leucine zipper or coiled-coil structure, or form part of a helix-loop-helix structure found in other dimeric transcription factors [ 1.51.
The oestrogen receptor binds to specific DNA sequences, termed oestrogen-response elements, which consist of inverted repeats of the sequence TGACC separated by three base pairs. The elements func:inn as typical transcriptional enhancers with perfect inverted repeats being most active. The structure of the DNA-binding domain has been determined by n.m.r. spectroscopy [ 161. The two zinc-finger motifs are found to be folded into a single domain. Amino acids near the first zinc coordination site, which are responsible for discrimi-Biochemical Society Transactions nating between an oestrogenand a glucocorticoid-response element form part of a helical structure that may interact with the major groove of the response element. Residues near the second zinc co-ordination site, which are implicated in the discrimination of the spacing between the half-sites [19] , may be involved in receptor monomer-monomer interactions.
The oestrogen receptor is able to stimulate transcription upon binding to oestrogen-response elements located in the vicinity of responsive genes. There appear to be two distinct TAFs, TAF-1 in the N-terminal domain the activity of which is oestrogen independent, and TAF-2 in the hormone-binding domain whose activity depends on the presence of oestrogen [6-9; Fig. 11 . The activities of TAF-1 and TAF-2 which are functionally distinct vary according to the responsive promoter and the target cell [6,8, 9, 201. T o summarize, it appears that oestrogen binding initially 'transforms' or activates the receptor by dissociating an oligomeric complex containing hsp 90, thereby favouring dimerization and high-affinity DNA binding, and subsequently induces a TAF located in the hormone-binding domain.
Mechanisms of action of hormone an tagon ists
A group of anti-oestrogens including tamoxifen, that also act as agonists, appear to promote dimerization and high-affinity DNA binding, but fail to induce the formation of TAF-2 in the hormonebinding domain [7, 9; Fig. 13 . Chambon and his coworkers have proposed that the agonist effect of tamoxifen is derived from TAF-1 in the N-terminal domain which is constitutively active [21] . The potency of tamoxifen as an antagonist or as an agonist probably reflects the relative contributions of TAF-1 and TAF-2 to promoter activity. Accordingly, in cells where the responsive promoter depends primarily on TAF-2 tamoxifen would be an antagonist, whereas where the promoter depends on TAF-1 activity tamoxifen could be an agonist.
'Pure anti-oestrogens' such as ICI 164 384, on the other hand, seem to inhibit receptor dimerization [22] . This inhibition is probably caused by steric interference produced by the large 7a-alkylamide extension present in ICI 164384 [23] since we have shown that the steroid-binding pocket is at or near the dimer interface [12] . We have now shown that ICI 164 384 markedly reduces the intracellular content of the oestrogen receptor by reducing its half-life and propose that this results from impaired receptor dimerization. As a consequence it appears that neither TAF-1 or TAF-2 are functional (Fig. 1) .
Concluding remarks
Tamoxifen is currently used successfully for the treatment of hormone-dependent breast cancer, with approximately 30% of patients responding to treatment [lo] . Since tamoxifen is not only an oestrogen antagonist but also a partial agonist, it is conceivable that a pure anti-oestrogen might be more effective. The initial choice of treatment might still be tamoxifen however, since few side-effects have been observed with the drug and pure antioestrogens might adversely affect conditions such Volume 19 as osteoporosis. Nevertheless, in time, tamoxifenresistant tumours often arise in patients and some of these could benefit from treatment with an antioestrogen, the mechanism of action of which is different from that of tamoxifen. It is important to establish whether other anti-oestrogens function by one or other of the mechanisms suggested for tamoxifen and ICI 164384 or by another novel means. Clearly, a better understanding of the mechanism of hormone antagonists is likely to lead to more efficacious treatment not only of breast cancer but also other endocrine disorders.
